NAVEE TECH Launches the Electric Scooter N40 in the Global Market
9.7.2022 19:39:00 EEST | Business Wire | Press release
Recently NAVEE Tech launched NAVEE N40 E-scooter which is exactly the kind of low-cost yet high-value electric scooters designed to help get more commuters onto two wheels. The new electric scooter offers comfortable, enjoyable, and joyful rides.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628006211/en/
(Photo: Business Wire)
The N40 comes equipped with high-capacity batteries providing impressive range capabilities which can run for nearly 40km without a charge. The 10-inch pneumatic tires, with superior shock absorption, make your ride smoother and more stable even on bumpy terrain or rough surfaces.
With 350watt Brushless Motor, N40’s output helping you conquer up to a 20% grade slope, and supports three different speed level. The maximum speed of N40 can reach 30 km/h. (Noted: The Brushless Motor of Nordic version is 250watt and the maximum speed can reach 20 km/h according to the laws and regulations). N40 is perfect for Nordic commuters.
What’s more, the Smart Battery Management system ensures battery safety and to notify you of any battery alerts when needed. The carefully tuned Dual Braking System utilize the advantage of disc braking and electric brake. With the quick folding system, the N40 can be easily folded almost in 3 seconds to store in the trunk.
The highlighted features of N40 are as below:
• Long range up to 40 km
• 18% superb uphill climbing ability
• 10 inch pneumatic tires
• Rated power 250watt brushless motor
• Max loading weight 100kg
• 15cm wide deck
• Front E-ABS brake with rear disc brake
• Three speed levels
• Support cruise control & energy recovery
• Ultra-bright front light
NAVEE TECH has a professional design and R&D team with rich experience in micro-mobility. The design and development of each product is based on the thorough understanding of customers’ requirements and pain points, as well as the full consideration of practicality, safety comfort at the stage of design and performance value.
In middle July, NAVEE N40 will be available at global market with only priced at €569.
About NAVEE TECH
NAVEE TECH, founded in 2020, is an innovative company specializing in the R&D, production, and distribution of e-scooters and e-bikes. NAVEE is committed to providing vehicles featuring the latest innovations & technology to global customers, and to making micro-mobility more smart, enjoyable, and convenient.
For more information, please visit http://naveetech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628006211/en/
Contact information
NAVEE TECH
Natalie Zhang
marketing@navee.tech; sales@navee.tech; service@navee.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom